Search results
Results from the WOW.Com Content Network
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India.It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
Kiran Mazumdar-Shaw (born 23 March 1953) is an Indian billionaire entrepreneur. [3] She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, [4] a biotechnology company based in Bangalore, India [5] and the former chairperson of Indian Institute of Management, Bangalore. [6]
If you are a shareholder in Biocon Limited’s (NSEI:BIOCON), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. [11] The transaction was completed in November 2022. [12]
The first Indian biotechnology company to be established was Biocon, which was founded by Kiran Mazumdar-Shaw in 1978. [3] The Indian biotechnology industry formally began in 1986 with the establishment of the Department of Biotechnology (DBT) by the Ministry of Science and Technology. [4]
Biocon, headquartered in Bengaluru, is the nation's leading biotechnology company and ranks 16th in the world in revenues. Institute of Bioinformatics and Applied Biotechnology (IBAB) , initiated by Biotechnology vision group, ICICI and Biocon (located at ITPL) is trying to shape revolutionary scientists in the field.
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Divi's Laboratories has between 60 and 85% global market share in generic naproxen, dextromethorphan and gabapentin APIs. [15] The company currently has between 20 and 30% global market share in pregabalin and methylamine APIs. [15] The company's API production is backwards integrated. [16]